How FDA could learn from oncology

Over the last two decades, scientific discoveries have propelled a surge in cancer drug development, but progress in bringing new medicines to patients has also relied on a less obvious factor. Innovative regulatory policies have been essential.

No one has had a greater influence over cancer drug regulation in the modern era than Richard Pazdur, director of FDA’s Oncology Center of Excellence. ...